Revuforj (Revumenib Citrate) Patent Expiration, LOE Window & CMS Spending
Revuforj (Revumenib Citrate) by Syndax: FDA Orange Book core substance LOE 2037-06-08 (last listed 2042-12-18), 0 AB generics, $1.1M 2024 CMS Part D & Medicaid spend, and $19,750 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Syndax |
| FDA Application & Pathway | N218944 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2037-06-08 |
| Last Listed Patent or Exclusivity Date | 2042-12-18 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.1M |
| 2024 Medicare Part D Spend | $1.1M |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($19,750 intro WAC) |